ATE204753T1 - Verfahren zur reduzierung von endotoxin induzierten effekten - Google Patents

Verfahren zur reduzierung von endotoxin induzierten effekten

Info

Publication number
ATE204753T1
ATE204753T1 AT96104316T AT96104316T ATE204753T1 AT E204753 T1 ATE204753 T1 AT E204753T1 AT 96104316 T AT96104316 T AT 96104316T AT 96104316 T AT96104316 T AT 96104316T AT E204753 T1 ATE204753 T1 AT E204753T1
Authority
AT
Austria
Prior art keywords
induced effects
endotoxin
reducing endotoxin
induced
medicament
Prior art date
Application number
AT96104316T
Other languages
English (en)
Inventor
Christer Grimfors
Ellinor Lampen
Svante Lindgren
Goeran Sandberg
Raymond Wahlen
Bjoern Westberg
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Application granted granted Critical
Publication of ATE204753T1 publication Critical patent/ATE204753T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT96104316T 1991-01-09 1991-12-20 Verfahren zur reduzierung von endotoxin induzierten effekten ATE204753T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar

Publications (1)

Publication Number Publication Date
ATE204753T1 true ATE204753T1 (de) 2001-09-15

Family

ID=20381566

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92903332T ATE157866T1 (de) 1991-01-09 1991-12-20 Verfahren zur entfernung von endotoxinen
AT96104316T ATE204753T1 (de) 1991-01-09 1991-12-20 Verfahren zur reduzierung von endotoxin induzierten effekten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92903332T ATE157866T1 (de) 1991-01-09 1991-12-20 Verfahren zur entfernung von endotoxinen

Country Status (11)

Country Link
EP (4) EP0719550B1 (de)
JP (1) JP3200604B2 (de)
AT (2) ATE157866T1 (de)
AU (1) AU9152891A (de)
DE (2) DE69132710T2 (de)
DK (2) DK0566644T3 (de)
ES (2) ES2163543T3 (de)
GR (1) GR3025573T3 (de)
PT (1) PT715849E (de)
SE (1) SE468881B (de)
WO (1) WO1992011847A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
EP0738146B1 (de) * 1994-01-11 2003-05-02 N.V. Nutricia Verfahren zur behandlung von stoehrungen des menschlichen oder tierischen koerpers durch verabreichung von aminosaeuren
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
DE69827149T2 (de) * 1997-08-15 2006-03-09 Fairbanks, Carolyn Ann, Rochester Agmatin für die behandlung neuropathischer schmerzen
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
WO2003026492A2 (en) 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
EP1910844B1 (de) 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta-struktur-bindende verbindungen
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
CA2655873C (en) 2006-07-14 2017-10-17 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA939265A (en) * 1967-11-18 1974-01-01 Yoshitaka Ikezuki Injectable compositions for alleviating the pain incurred from administrations of injections
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
JPH01238534A (ja) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc エンドトキシンの除去方法
US5019558A (en) * 1988-05-09 1991-05-28 Georges Cehovic Method for treating memory disturbances using arginine aspartate
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation

Also Published As

Publication number Publication date
EP0715849A1 (de) 1996-06-12
JP3200604B2 (ja) 2001-08-20
DK0566644T3 (da) 1998-04-27
ATE157866T1 (de) 1997-09-15
DE69223426D1 (de) 1998-01-15
EP0566644B1 (de) 1997-09-10
AU9152891A (en) 1992-08-17
EP0566644A1 (de) 1993-10-27
EP0715849B1 (de) 2001-07-25
DE69132710D1 (de) 2001-10-04
JPH06504058A (ja) 1994-05-12
EP0719550B1 (de) 2001-08-29
EP0719550A2 (de) 1996-07-03
ES2109338T3 (es) 1998-01-16
DK0719550T3 (da) 2001-12-10
WO1992011847A1 (en) 1992-07-23
EP0494848A1 (de) 1992-07-15
SE468881B (sv) 1993-04-05
DE69132710T2 (de) 2002-04-18
EP0494848B1 (de) 1997-03-26
PT715849E (pt) 2002-01-30
GR3025573T3 (en) 1998-03-31
EP0719550A3 (de) 1996-07-24
DE69223426T2 (de) 1998-03-12
ES2163543T3 (es) 2002-02-01
SE9100059L (sv) 1992-07-10
SE9100059D0 (sv) 1991-01-09

Similar Documents

Publication Publication Date Title
ATE204753T1 (de) Verfahren zur reduzierung von endotoxin induzierten effekten
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
CA2159450A1 (en) 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
DE69413237D1 (en) Plättchenaggregationsinhibitoren
HU9201578D0 (en) A new peptide and method for producing it
CA2140927A1 (en) Platelet aggregation inhibitors
NO944915D0 (no) Öking av trambomodulinekspresjon
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
DE69530123D1 (en) Plättchenaggregationsinhibitoren
IL108068A0 (en) Cephem derivatives and pharmaceutical compositions containing the same
HU9401159D0 (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee